Pfizer's Q3 Earnings Surpasses Estimates, Lifts Forecasts For COVID-19 Vaccine Sales By $2B

  • Pfizer Inc PFE has reported a Q3 adjusted EPS of $1.78, up 40% Y/Y, well ahead of the consensus of $1.47. 
  • The company achieved revenues of $22.64 billion, down 6%, beating the Wall Street estimate of $21.37 billion.
  • Its COVID-19 vaccine, Comirnaty, contributed $4.4 billion in direct sales and alliance revenues, down from $12.98 billion a year ago.
  • COVID-19 treatment Paxlovid contributed $7.51 billion in global sales.
  • Albert Bourla, Chairman and CEO, stated, "Over the next 18 months, we expect to have up to 19 new products or indications in the market – including the five for which we have already begun co-promotion or commercialization earlier this year. Many of these 19 programs are already largely de-risked from a clinical perspective, the majority were discovered in-house, and nearly all would be for indications outside of COVID-19."
  • FY22 Outlook: Pfizer revised FY22 sales of $99.5 billion - $102 billion versus the consensus of $99.6 billion and the prior guidance of $98-$102 billion.
  • The company has revised adjusted EPS guidance to $6.40 - $6.50 versus the earlier guidance of $6.30 - $6.45 and the consensus of $6.38.
  • Pfizer raised COVID-19 vaccine sales guidance by 2 billion to $34 billion and around $22 billion in revenue for Paxlovid.
  • Price Action: PFE shares are up 3.97% at $48.40 during the premarket session on the last check Tuesday.
  • Photo via Wikimedia Commons
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CarePre-Market OutlookMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccinewhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!